Biomarker may affect chemo resistance in patients with advanced ovarian cancer
the ONA take:
miR-506, a non-coding RNA molecule that helps to control gene expression, may play a role in chemotherapy resistance in patients with ovarian cancer, according to a recent study published in the Journal of the National Cancer Institute.
Wei Zhang, PhD, of the MD Anderson Cancer Center and fellow researchers looked at patient data from The Cancer Genome Atlas and other independent clinical populations. In previous studies, they noted that the miR-506 molecule had the potential to sensitize cancer cells to chemotherapy.
In the present study, they found that response to chemotherapy drugs such as cisplatin and olaparib in epithelial ovarian cancer was significantly improved when miR-506 was added to the treatment.
“miR-506 was associated with better response to therapy and longer progression-free and overall survival,” Dr. Zhang said.
Previous studies found that the molecule was a potent inhibitor of epithelial-to-mesenchymal transition, which is associated with chemoresistance.
“This study provides further insight into this molecule’s role in augmenting chemotherapy responses by directly affecting the DNA repair process used by cancer cells to counter DNA damages caused by chemotherapy,” Dr. Zhang said.
miR-506 may play a role in chemotherapy resistance in patients with ovarian cancer.
- Response to Anemia Treatment Differs in Lymphoma, Multiple Myeloma
- Fertility Preservation in Male Adolescents and Young Adults With Cancer
- Impact of Prostate Cancer Diagnosis, Treatment Choice on Quality of Life
- Social, Psychiatric Variables Reduce Cognitive Functioning, QoL in HNC
- Axillary Lymph Node Dissection Predictive for Lymphedema in Breast Cancer
- HPV and Cancer (Fact Sheet)
- Pain Control More Easily Achieved With Nurse-Led Education in Bone Metastases
- Acupuncture an Effective Alternative Treatment for Cancer-Related Fatigue
- Using Nutrition-Based Strategies to Manage Adverse Effects of Cancer
- Palliative Care Associated With Decreased Costs For Patients With Advanced Cancer
- Refined Equation May Obviate Oncotype DX in Breast Cancer Treatment Decisions
- Risk Factors for Brain Metastases in HER2+ Breast Cancer Identified in Analysis
- Intermediate Oncotype DX Scores Prognostic of OS in Early-stage Breast Cancer
- Colorectal Cancer and Dietary Fiber: Source Is More Important Than Amount
- Reduced Delayed Intensification Impacts Risk of Pediatric ALL Relapse
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|